Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis.
Evaluation and Treatment of Hypertension in End-Stage Renal Disease Patients on Hemodialysis.
复制标题
血液透析终末期肾病患者高血压的评估和治疗。
DOI：
10.1007/s11886-016-0805-y
复制
发表时间：
2016
影响因子：
3.7
通讯作者：
VanBuren,PeterNoel
中科院分区：
文献类型：
--
作者：
VanBuren,PeterNoel
高血压是终末期肾脏疾病血液透析患者最常见的心血管合并症之一。其复杂的病理生理机制与细胞外容量过载、尿毒症相关因素引起的血管阻力增加或肾脏衰竭的异常信号，以及血液透析治疗期间和治疗之间发生的独特血压变化有关。尽管血液透析患者的血压随时间的变化而变化，但在血液透析单位内或外诊断出的高血压与心血管发病率和死亡率增加有关。这篇综述详细介绍了血液透析患者高血压的原因，并提供了高血压的临床后果和管理的最新综述。
Hypertension is one of the most common cardiovascular comorbidities in end-stage renal disease patients on hemodialysis. Its complex pathophysiology is related to extracellular volume overload, increased vascular resistance stemming from factors related to uremia or abnormal signaling from the failing kidneys, as well as the unique blood pressure changes that take place during and between hemodialysis treatments. Despite the changing nature of blood pressure over time in hemodialysis patients, hypertension diagnosed in or out of the hemodialysis unit is associated with increased cardiovascular morbidity and mortality. This review details the causes of hypertension in hemodialysis patients and provides an updated review of the clinical consequences and management of hypertension.